526953 Stock Overview Engages in the pharmaceutical business in India and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Venus Remedies Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Venus Remedies Historical stock prices Current Share Price ₹313.15 52 Week High ₹429.60 52 Week Low ₹280.00 Beta 1.14 1 Month Change 4.42% 3 Month Change -8.52% 1 Year Change -19.84% 3 Year Change -16.62% 5 Year Change 1,270.46% Change since IPO 726.25%
Recent News & Updates
Second quarter 2025 earnings released: EPS: ₹2.63 (vs ₹7.44 in 2Q 2024) Oct 30
Now 22% undervalued after recent price drop Oct 22
Venus Remedies Limited to Report First Half, 2025 Results on Oct 29, 2024 Oct 18
Now 22% undervalued after recent price drop Oct 03
Venus Remedies Limited Announces Executive Appointments Sep 24 Venus Remedies Limited to Report Q2, 2025 Results on Nov 14, 2024 See more updates
Second quarter 2025 earnings released: EPS: ₹2.63 (vs ₹7.44 in 2Q 2024) Oct 30
Now 22% undervalued after recent price drop Oct 22
Venus Remedies Limited to Report First Half, 2025 Results on Oct 29, 2024 Oct 18
Now 22% undervalued after recent price drop Oct 03
Venus Remedies Limited Announces Executive Appointments Sep 24 Venus Remedies Limited to Report Q2, 2025 Results on Nov 14, 2024
Venus Remedies Limited, Annual General Meeting, Sep 23, 2024 Aug 14
First quarter 2025 earnings released: EPS: ₹0.92 (vs ₹0.88 in 1Q 2024) Aug 14
Venus Remedies Limited to Report Q1, 2025 Results on Aug 13, 2024 Aug 01
Now 21% overvalued after recent price rise Jul 01
Now 21% overvalued after recent price rise Jun 28
Now 27% overvalued after recent price rise Jun 13
Investor sentiment improves as stock rises 16% Jun 12
Full year 2024 earnings released: EPS: ₹21.31 (vs ₹19.87 in FY 2023) Jun 05
Venus Remedies Limited to Report Q4, 2024 Results on May 30, 2024 May 20
Investor sentiment improves as stock rises 16% Apr 03
Third quarter 2024 earnings released: EPS: ₹5.13 (vs ₹2.46 in 3Q 2023) Feb 15
Venus Remedies Limited to Report Q3, 2024 Results on Feb 14, 2024 Feb 03
Second quarter 2024 earnings released: EPS: ₹7.44 (vs ₹3.99 in 2Q 2023) Nov 13
Investor sentiment improves as stock rises 23% Nov 10
Now 20% undervalued Oct 31
Venus Remedies Limited to Report Q2, 2024 Results on Nov 09, 2023 Oct 28
New minor risk - Share price stability Oct 18
Investor sentiment improves as stock rises 20% Oct 18
Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs Oct 17
Investor sentiment deteriorates as stock falls 15% Aug 22
New minor risk - Profit margin trend Aug 16
Venus Remedies Limited to Report Q1, 2024 Results on Aug 14, 2023 Aug 04
Full year 2023 earnings released: EPS: ₹19.87 (vs ₹30.86 in FY 2022) Jul 25
Venus Remedies Limited, Annual General Meeting, Aug 24, 2023 Jul 15
Investor sentiment improves as stock rises 16% Jul 10
Venus Remedies Limited Receives Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities Jun 09
Full year 2023 earnings released: EPS: ₹19.88 (vs ₹30.86 in FY 2022) Jun 02
Investor sentiment improves as stock rises 18% May 30
Investor sentiment improves as stock rises 20% Apr 17
Less than half of directors are independent Apr 14
Third quarter 2023 earnings released: EPS: ₹2.46 (vs ₹4.22 in 3Q 2022) Jan 31
Second quarter 2023 earnings released: EPS: ₹3.99 (vs ₹17.32 in 2Q 2022) Nov 16
First quarter 2023 earnings released: EPS: ₹5.16 (vs ₹8.86 in 1Q 2022) Jul 31 Venus Remedies Limited to Report Q2, 2023 Results on Nov 14, 2022
Venus Remedies Limited, Annual General Meeting, Aug 23, 2022 Jul 26
Venus Remedies Limited to Report Q1, 2023 Results on Jul 30, 2022 Jul 24
Now 21% undervalued after recent price drop Jul 19
Chairman recently bought ₹28m worth of stock Jun 02
Full year 2022 earnings released: EPS: ₹30.86 (vs ₹50.05 in FY 2021) May 30
Now 26% undervalued after recent price drop May 30
Venus Remedies Limited Appoints Akshansh Chaudhary as Additional Director (Whole Time Director) May 28
Investor sentiment improved over the past week May 19
Venus Remedies Limited to Report Q4, 2022 Results on May 27, 2022 May 17
Investor sentiment improved over the past week Apr 05
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 02
Investor sentiment deteriorated over the past week Dec 16
Second quarter 2022 earnings released: EPS ₹17.32 (vs ₹10.55 in 2Q 2021) Nov 02
Investor sentiment improved over the past week Oct 18
First quarter 2022 earnings released: EPS ₹8.86 (vs ₹6.08 in 1Q 2021) Aug 15
Investor sentiment improved over the past week Aug 04
Investor sentiment improved over the past week Jun 30
Full year 2021 earnings released: EPS ₹50.04 (vs ₹8.10 loss in FY 2020) Jun 03
Venus Remedies Limited announced that it has received INR 137.52425 million in funding Jun 01
Investor sentiment improved over the past week Mar 22
New 90-day high: ₹228 Mar 09
Investor sentiment improved over the past week Feb 18
Third quarter 2021 earnings released: EPS ₹9.44 (vs ₹0.78 loss in 3Q 2020) Feb 10
New 90-day high: ₹185 Feb 09
Investor sentiment improved over the past week Jan 01
New 90-day high: ₹166 Jan 01 Venus Remedies Limited to Report Q3, 2021 Results on Feb 15, 2021
Venus Remedies Limited, Annual General Meeting, Dec 02, 2020 Nov 07
Venus Remedies Limited to Report Q2, 2021 Results on Nov 06, 2020 Nov 01
New 90-day high: ₹152 Oct 05
New 90-day high - ₹116 Sep 15
Full year earnings released - ₹8.10 loss per share Sep 14
Venus Remedies Limited to Report Q1, 2021 Results on Sep 15, 2020 Sep 06
New 90-day high - ₹110 Aug 20
New 90-day high - ₹91.00 Aug 05
Venus Remedies Limited to Report Q4, 2020 Results on Jul 31, 2020 Jul 26
New 90-day high - ₹65.10 Jul 21 Shareholder Returns 526953 IN Pharmaceuticals IN Market 7D -6.0% 0.8% -4.2% 1Y -19.8% 39.7% 19.1%
See full shareholder returns
Return vs Market: 526953 underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility Is 526953's price volatile compared to industry and market? 526953 volatility 526953 Average Weekly Movement 5.7% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 526953 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 526953's weekly volatility (6%) has been stable over the past year.
About the Company Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones, immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, solvent, respiratory, and anticoagulant. It is also involved in the provision of portfolio of herbal products.
Show more Venus Remedies Limited Fundamentals Summary How do Venus Remedies's earnings and revenue compare to its market cap? 526953 fundamental statistics Market cap ₹4.19b Earnings (TTM ) ₹221.11m Revenue (TTM ) ₹6.15b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 526953 income statement (TTM ) Revenue ₹6.15b Cost of Revenue ₹3.76b Gross Profit ₹2.38b Other Expenses ₹2.16b Earnings ₹221.11m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) 16.54 Gross Margin 38.79% Net Profit Margin 3.60% Debt/Equity Ratio 8.3%
How did 526953 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 21:43 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ashish Kushwaha FirstCall Research Nagaraju Airruva FirstCall Research
Show 0 more analysts 
